- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02515877
Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers (HPV-RX)
June 8, 2016 updated by: Gustave Roussy, Cancer Campus, Grand Paris
Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Phase I Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers
The treatment of cervical tumors depends on the stage of the disease.
In advanced forms (nodal and / or local extension to the vagina and / or parameters) , radiotherapy associated with curietherapy , plays a major role.
Until recently this association was the standard treatment for advanced stage uterine cancer.
With this combination, rates of local failures (evolutionary prosecution and local recurrences) were 20 to 50% in stages IIb and 50-75 % for stage III.
More than 50% for patients with a cervical cancer locally advanced (FIGO stages II / IV) .
The standard treatment, external radiotherapy followed by curietherapy allows expect survival rates at 5 years for approximately 30-45 %.
For ten years, numerous studies have evaluated the addition of concurrent chemotherapy to radiotherapy in cancer of the cervix.
More than 19 randomized trials have been published.
A meta-analysis of these trials was undertaken to assess the role of radiochemotherapy in cancers of the cervix.
The first meta-analysis published by the Cochrane Collaborative Group, taking into account 4580 patient, shows an improvement in survival, both in terms of progression free survival and overall survival for patients treated with radio chemotherapy respectively 16% and 12 % (p < 0.0001).
The rate of metastasis is also decreased (p < 0.0001).
Survival rates were significantly better when platinum salt was used ( p < 0.0001 ) .
However, no clinical benefit of chemoradiotherapy has been demonstrated for tumors stages [1, 2] locally advanced, possibly due to small number of patients.
The investigators have previously shown that antiviral agents used in preclinical models, Cidofovir® causes the selective radiosensitization of cells infected by the papillomavirus (HPV).
This trial proposes to study a new concept to increase radiochemotherapy efficiency: the modulation of the expression of viral oncoproteins HPV virus by an antiviral agent.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Val de Marne
-
Villejuif, Val de Marne, France, 94805
- Gustave Roussy Cancer Campus Grand Paris
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients with cervix cancer : Squamous cell carcinoma or adenocarcinoma of stage IB2> 4 cm, II, III or IVA (International Federation of Gynecology Obstetrics, regardless of pelvic lymph node status (optional surgical exploration) without paraaortic metastasis.
- Detection of the virus genome of HPV positive on the primary tumor.
- General state ECOG performance status 0-1.
- 18 </ = age </ = 70 years.
- PN> 2000 / mm3
- hemoglobin> 9 g/l after transfusion if necessary .
- platelets > 100 000 / mm3
- Serum creatinine <1.5 upper limit of normal.
- Liver function tests (SGOT, SGPT, alkaline phosphatase and bilirubin) <1.5 upper limit of normal.
- Life expectancy> 3 months.
- Systematic Beta HCG Dosage for premenopausal women.
- Informed consent signed after informing the patient.
- Proteinuria <2g / L (200mg / dL) and creatinine clearance of> / = 55 ml / min.
Exclusion Criteria:
- Other histological types of cervix tumor than those mentioned in the inclusion criteria.
- Search of viral sequences on the negative HPV tumor diagnosis.
- History of cancer other than basal cell carcinoma.
- Pre-treatment with radiotherapy or chemotherapy.
- Ongoing pregnancy.
- History or active psychiatric illness.
- Nephropathy whatever the grade.
- Infection scalable.
- Active infection or other serious underlying pathology may prevent the patient receiving the treatment (in particular hepatic or cardiac).
- Inclusion in another clinical trial protocol with an experimental molecule (during the study or within one month before inclusion).
- Inability to submit to medical monitoring study for geographical, social or psychological.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiotherapy + Vistide + Chemoterapy
|
External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
AUC= 2,5 (Calvert formula)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose limiting toxicity
Time Frame: Assessed every week after inclusion up to 10 weeks
|
Assessed every week after inclusion up to 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Using RECIST criteria
Time Frame: Assessed 14 weeks after inclusion
|
Using RECIST criteria
|
Assessed 14 weeks after inclusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
August 3, 2015
First Submitted That Met QC Criteria
August 4, 2015
First Posted (Estimate)
August 5, 2015
Study Record Updates
Last Update Posted (Estimate)
June 9, 2016
Last Update Submitted That Met QC Criteria
June 8, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-005505-21
- 2007/1297 (Other Identifier: CSET number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on External radiotherapy + curietherapy
-
Centre Francois BaclesseTerminatedProstate Cancer With Intermediate RiskFrance
-
Peking University Third HospitalNot yet recruitingEndometrial Cancer | Radiotherapy | PathologyChina
-
Consorci Sanitari de TerrassaCompletedLocalized Prostate Carcinoma | Predictive Cancer Model
-
International Atomic Energy AgencyTata Memorial Centre; University of Maryland, College Park; Centro de Lucha contra... and other collaboratorsUnknownSquamous Cell Carcinoma of the Head and NeckIndia, Argentina, Cuba, Indonesia, Pakistan, Philippines, South Africa, Thailand, Uruguay
-
The Netherlands Cancer InstituteRoyal Marsden NHS Foundation TrustTerminatedSarcoma | Soft Tissue SarcomasUnited Kingdom, Netherlands
-
European Institute of OncologyCompletedCarcinoma BreastItaly
-
European Institute of OncologyActive, not recruitingAdenocarcinoma of ProstateItaly
-
University of StellenboschUnknown
-
University Hospital MuensterDeutsche Krebshilfe e.V., Bonn (Germany)Completed
-
Rigshospitalet, DenmarkDanish Center for Interventional Research in Radiation Oncology (CIRRO)Terminated